In a small study, researchers assessed the mechanistic basis of unusual vertical jerky eye oscillations seen in patients clinically diagnosed with progressive supranuclear palsy.
Researchers assessed the safety and efficacy of tilavonemab for treating progressive supranuclear palsy, a neurodegenerative disorder linked to tau protein aggregation.
The FDA has granted Orphan Drug designation to RT001 (Retrotope) for the treatment of progressive supranuclear palsy (PSP).
While parkinsonian disorders share a common mechanism of protein aggregation, manifestations are quite varied.
New guidelines for progressive supranuclear palsy provide very specific and sensitive criteria that allow for identification of clinical features of the disease at much earlier stages.
